Related references
Note: Only part of the references are listed.Lower odds of cardiac events for gonadotropic releasing hormone antagonists versus agonists.
Eugene Blanchard Cone et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases
Gincy George et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2019)
The risk of cardiovascular disease following GnRH agonists versus antagonists: Real-world evidence from four European countries
G. George et al.
EUROPEAN UROLOGY SUPPLEMENTS (2018)
Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data
Lucie-Marie Scailteux et al.
EUROPEAN JOURNAL OF CANCER (2017)
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Timothy J. Wilt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Acute Myocardial Infarction
Jeffrey L. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
Marc L. Berger et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology
Julien Bezin et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Data Resource Profile: The Scottish National Prescribing Information System (PIS)
Samantha Alvarez-Madrazo et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2016)
Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Cecilia Bosco et al.
EUROPEAN UROLOGY (2015)
Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
Sean O'Farrell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2014)
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Peter C. Albertsen et al.
EUROPEAN UROLOGY (2014)
GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model
Sarah N. Hopmans et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Evaluating the Impact of Database Heterogeneity on Observational Study Results
David Madigan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials
Paul L. Nguyen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels.
Aurelian Radu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
GnRH blockers: a changing paradigm in the management of prostate cancer
Lawrence Drudge-Coates
INTERNATIONAL JOURNAL OF UROLOGICAL NURSING (2009)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
Henry K. Tsai et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Christopher S. Saigal et al.
CANCER (2007)
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
Anthony V. D'Amico et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD
AAT Monfared et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2006)
Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females - Molecular insights into gender differences in atherosclerosis
MKC Ng et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall
H Hanke et al.
CIRCULATION (2001)
A comparison of observational studies and randomized, controlled trials.
K Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
